Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lane Labs USA

This article was originally published in The Tan Sheet

Executive Summary

House Government Reform Committee Chairman Dan Burton (R-Ind.) questions FDA's actions against Lane's BeneFin, SkinAnswer and MGN-3 products in a March 27 letter. The agency, in a Dec. 8 complaint filed in Newark, N.J. federal court, is seeking a permanent injunction against the sale of the products, stating they are "unapproved drugs" (1"The Tan Sheet" Dec. 20, 1999, p. 5). Burton notes Lane Labs is testing BeneFin's anti-cancer effects under an IND application, but if "each manufacturer is going to be sued by the FDA for conducting research, then a disincentive has been created." Saying he has received over 300 letters from consumers in support of Lane Labs, the Indiana Republican advises FDA to "create a category of research application specifically tailored to dietary supplements so that research is encouraged...and companies are not at risk for legal action"

You may also be interested in...



Lane Labs FTC Settlement To Fund National Cancer Institute Study

Lane Labs has been ordered by the Federal Trade Commission to contribute $450,000 to fund a National Cancer Institute clinical study on the effects of shark cartilage supplementation on cancer as part of a $1 mil. settlement of charges it made unsubstantiated cancer claims for its dietary supplements.

Lane Labs FTC Settlement To Fund National Cancer Institute Study

Lane Labs has been ordered by the Federal Trade Commission to contribute $450,000 to fund a National Cancer Institute clinical study on the effects of shark cartilage supplementation on cancer as part of a $1 mil. settlement of charges it made unsubstantiated cancer claims for its dietary supplements.

Lane Labs FTC Settlement To Fund National Cancer Institute Study

Lane Labs has been ordered by the Federal Trade Commission to contribute $450,000 to fund a National Cancer Institute clinical study on the effects of shark cartilage supplementation on cancer as part of a $1 mil. settlement of charges it made unsubstantiated cancer claims for its dietary supplements.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS091068

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel